Eduardo Villa

Eduardo Villa

Auto-generated profile, based on publicly available information

Eduardo Villa

Faculty of Medicine, Hospital Clínico José Joaquín Aguirre, Universidad de Chile, Santos Dumont 999, Santiago, Chile

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
EVEduardo Villa
Eduardo Villa
TSTeresita Sarquis
Teresita Sarquis
JGJosé de Grazia
José de Grazia
RNRené Núñez
René Núñez
PAPablo Alarcón
Pablo Alarcón
CGCarlos Guevara
Carlos Guevara

1 September 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CGCarlos Guevara
Carlos Guevara
EVEduardo Villa
Eduardo Villa
MCMarcela Cifuentes
Marcela Cifuentes
RNRodrigo Naves
Rodrigo Naves
JGJosé de Grazia
José de Grazia

1 April 1998 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
OGOlga González-Albarrán
Olga González-Albarrán
LRLuis M. Ruilope
Luis M. Ruilope
EVEduardo Villa
Eduardo Villa
RRRafael Garcı́a Robles
Rafael Garcı́a Robles

21 August 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
EVEduardo Villa
Eduardo Villa
Luciano SasoLuciano Saso
Luciano Saso
Silvia ChichiarelliSilvia Chichiarelli
Silvia Chichiarelli
Catalina Rojas-SoléCatalina Rojas-Solé
Catalina Rojas-Solé
VGVíctor Pinilla González
Víctor Pinilla González
RRRamón Rodrigo
Ramón Rodrigo
Acute myocardial infarction (AMI) is one of the main causes of mortality worldwide. Currently, the most effective treatment is percutaneous coronary angioplasty (PCA). However, paradoxically, the restoration of blood flow induces myocardial reperfusion injury (MRI), contributing up to 50% of the final infarct size. Oxidative stress, characterized by a burst of reactive oxygen species (ROS) following reperfusion, plays a fundamental role in its pathophysiology, causing inflammation, endothelial dysfunction, and cell death mainly through autophagy, apoptosis, ferroptosis, necroptosis, and pyroptosis. To mitigate these injury mechanisms, numerous antioxidant strategies have been evaluated using both in vitro and in vivo models with promising results, but limited benefit when tested in humans. Several antioxidants have biological properties that counteract ROS-induced damage by acting as ROS scavengers, metal chelators, and antioxidant enzyme enhancers. In this review, we focus on the mechanisms by which oxidative stress induces cell death after AMI and highlight the most promising therapeutic antioxidant agents that could provide comprehensive protection against MRI. A multitarget cardioprotective strategy, combining interventions with strong preclinical evidence, could provide a more effective approach for reducing MRI. Our study aims to bridge the gap between basic and clinical research and explore the potential clinical applications of antioxidants.

15 November 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
EVEduardo Villa
Eduardo Villa
RNRodrigo Naves
Rodrigo Naves
KBKatiuska Bezares
Katiuska Bezares
KCKaren Cobeña
Karen Cobeña
AVAna Claudia Villarroel
Ana Claudia Villarroel
CGCarlos Guevara
Carlos Guevara
Statins are the first line of treatment for hypercholesterolemia and of prevention of atherosclerotic cardiovascular disease (ASCVD). It is estimated that one in four Americans over the age of 40 years use statins. In rare cases patients may develop an autoimmune myopathy associated with antibodies against 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). Anti-HMGCR associated myopathy requires immediate discontinuation of statins plus initiation of immunosuppressive therapy. Suspension of statin treatment worsens low-density lipoprotein-cholesterol (LDL-C) control, leading to an increased risk of ASCVD and necessitating commencement of another treatment for dyslipidemia. Unfortunately, the management of dyslipidemia in these patients is still unclear. Herein, we describe the case of a 65-year-old woman with dyslipidemia treated with atorvastatin, who consulted for long-standing muscle pain associated with symmetrical proximal weakness. Laboratory tests showed elevated levels of creatine kinase and anti-HMGCR antibodies. She was diagnosed with an anti-HMGCR associated myopathy and was successfully treated with corticosteroids and azathioprine as immunosuppressive therapy, followed by ezetimibe for LDL-C reduction. We present key findings for early recognition and treatment of anti-HMGCR associated myopathy and give recommendations on how to manage hypercholesterolemia in a patient with statin intolerance due to this disease.

1 July 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CGCarlos Guevara
Carlos Guevara
EVEduardo Villa
Eduardo Villa
VDVioleta Diaz
Violeta Diaz
CGCristian Garrido
Cristian Garrido
MMMelissa Martinez
Melissa Martinez
JGJosé de Grazia
José de Grazia